Nektar Therapeutics (NKTR) Financials
Key financial figures for Nektar Therapeutics (Q2 2026).
Nektar Therapeutics reported revenue of $10.1 million for Q2 FY2026, down 9.3% from the same period a year earlier. The company posted a net loss of $40.6 million, or -$1.23 per share. Operating margin came to -417.94%, against -324.21% a year earlier. Free cash flow for the period was -$75.9 million. Across the last 5 reported quarters, quarterly revenue has moved from $11.2 million in Q2 FY2025 to $10.1 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Nektar Therapeutics are on the SentiSense financials page.
- Revenue
- $10M
- Net Income
- -$41M
- EPS
- $-1.23
- Total Assets
- $1.1B
- Operating Cash Flow
- -$76M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $10M | -$41M | -$1.23 | -417.94% | -$76M |
| Q1 FY2026 | $11M | -$45M | -$1.82 | -352.25% | -$44M |
| Q4 FY2025 | $22M | -$36M | -$1.78 | -87.54% | -$65M |
| Q3 FY2025 | $12M | -$36M | -$1.87 | -267.45% | -$49M |
| Q2 FY2025 | $11M | -$42M | -$2.95 | -324.21% | -$46M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $55M | -$164M | -$9.73 | -236.77% | -$209M |
| FY2024 | $98M | -$119M | -$8.68 | -106.88% | -$177M |
| FY2023 | $90M | -$276M | -$21.79 | -152.49% | -$193M |
Frequently asked questions
What was Nektar Therapeutics's revenue last quarter?
Nektar Therapeutics reported revenue of $10.1 million for Q2 FY2026, down 9.3% from the same period a year earlier.
Is Nektar Therapeutics profitable?
Not in its most recent reported period. Nektar Therapeutics reported a net loss of $40.6 million for Q2 FY2026, a net margin of -400.97% on revenue.
How has Nektar Therapeutics's margin trended?
Operating margin was -417.94% in Q2 FY2026, compared with -324.21% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
When does Nektar Therapeutics report next?
Nektar Therapeutics is scheduled to report Q3 2026 results on 2026-11-12. The company has confirmed that date.
Full income statement, balance sheet and cash flow for Nektar Therapeutics on SentiSense, with up to forty quarters and twenty fiscal years of history.